This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT01925209 |
|---|---|
| Status | Completed |
| Phase | Phase 2 / Phase 3 |
| Sponsor | Novartis Pharmaceuticals |
| Enrollment | 251 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Sporadic Inclusion Body Myositis |
| Interventions | BYM338/bimagrumab; Placebo |
| Start | Sep 26, 2013 |
| Primary completion | Jan 6, 2016 |
| Study completion | Jan 6, 2016 |
| Results posted | Yes, in the registry |
| Registry last updated | Aug 11, 2017 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change From Baseline in 6 Minute Walking Distance (6MWD) Test at Week 52 | Baseline, Week 52 |
5 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
